Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease

Journal of Hepatology

Volumn 26, Issue 6, 1997, Pages 1213-1219

  Murawaki, Yoshikazu ^a   Ikuta, Yujiro ^a   Idobe, Youko ^a   Kitamura, Yukisato ^a   Kawasaki, Hironaka ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Liver disease; TIMP 1

Indexed keywords

SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; ARTICLE; CHRONIC ACTIVE HEPATITIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0030741845     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80454-0     Document Type: Article

References (34)

1. Cawston TE. Protein inhibitors of metalloproteinases. Barrett AJ, Salvesen G. Proteinase Inhibitors. 1986;589-610 Elsevier, Amsterdam.
2. Murphy G, Docherty AJP. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol. 7:1992;120-125.
3. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloproteinases. Method Enzymol. 248:1995;496-510.
4. Murawaki Y, Yamamoto H, Kawasaki H, Shima H. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma. Clin Chim Acta. 218:1993;47-58.
5. Murawaki Y, Koda M, Yamada S, Kawasaki H, Shima H, Burkhardt H. Serum collagenase activity in patients with chronic liver disease. J Hepatol. 18:1993;328-234.
6. Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. Hepatology. 20:1994;780-787.
7. Muzzillo DA, Imoto M, Fukuda Y, Koyama Y, Saga S, Nagai Y, Hayakawa T. Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver disease. J Gastroenterol Hepatol. 8:1993;437-441.
8. Li J, Rosman AS, Leo MA, Nagai Y, Lieber CS. Tissue inhibitor of metalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholic patients and can serve as a marker of fibrosis. Hepatology. 19:1994;1418-1423.
9. Barsky SH, Gopalakrishna R. High metalloproteinase inhibitor content of human cirrhosis and its possible conference of metastasis resistance. J Natl Cancer Inst. 80:1988;102-108.
10. Iredale JP, Goddard S, Murphy G, Benyon RC, Arthur MJP. Tissue inhibitor of metalloproteinase-1 and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. Clin Sci. 89:1995;75-81.
11. Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJP. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology. 110:1996;821-831.
12. Groote J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, et al. A classification of chronic hepatitis. Lancet. 11:1968;621-628.
13. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
14. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1994;1513-1520.
15. Dean DD, Martel-Pelletier J, Pelletier J-P, Howell DS, Woessner JF Jr. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest. 84:1989;678-685.
16. Kodama S, Iwata K, Iwata H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases: an application for rheumatoid arthritis serum and plasma. J Immunol Method. 127:1990;103-108.
17. Manicourt D-H, Fujimoto N, Obata K, Thonar EJ-MA. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis: relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum. 38:1995;1031-1039.
18. Maruyama K, Feiman S, Fainsilber Z, Nakano M, Okazaki I, Lieber CS. Mammalian collagenase increases in early alcoholic liver disease and decreases with cirrhosis. Life Sci. 30:1982;1379-1384.
19. Maruyama K, Okazaki I, Shigeta Y, Ishii H, Tsuchiya M. Type-specific collagen-degrading enzyme activity and serum type-III procollagen amino-peptide in various alcoholic liver diseases. Hirayama C, Kivirikko KI. Pathobiology of Hepatic Fibrosis. 1985;131-140 Elsevier Science Publishers, Amsterdam.
20. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-β1 in human fibroblasts. J Biol Chem. 266:1991;14064-14071.
21. Wright JK, Cawston TE, Hazleman BL. Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts. Biochim Biophys Acta. 1094:1991;207-210.
22. Chua CC, Chua BHL. Tumor necrosis factor-α induces mRNA for collagenase and TIMP in human skin fibroblasts. Connect Tissue Res. 25:1990;161-170.
23. Murphy G, Reynold JJ, Werb Z. Biosynthesis of tissue inhibitor of metalloproteinases by human fibroblasts in culture: stimulation by 12-o-tetradecanoylphorbol 13-acetate and interleukin-1 in parallel with collagenase. J Biol Chem. 260:1985;3079-3083.
24. Lotz M, Guerne PA. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA). J Biol Chem. 266:1991;2017-2020.
25. Castilla A, Prieto J, Fausto N. Transforming growth factors β1 and α in chronic liver disease: effects of interferon alpha therapy. N Engl J Med. 324:1991;933-940.
26. Annoni G, Weiner FR, Zern MA. Increased transforming growth factor-β1 gene expression in human liver disease. J Hepatol. 14:1992;259-264.
27. Roulot D, Durand H, Coste T, Rautureau J, Strosberg AD, Benarous R, Marullo S. Quantitative analysis of transforming growth factor β1 messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. Hepatology. 21:1995;298-304.
28. Napoli J, Bishop GA, McCaughan GW. Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis. Gastroenterology. 107:1994;789-798.
29. Murawaki Y, Nishimura Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Plasma transforming growth factor-β1 concentrations in patients with chronic liver disease. [Submitting].
30. Murawaki Y, Ikuta Y, Nishimura Y, Koda M, Kawasaki H. Serum markers for fibrosis and plasma transforming growth factor-β1 in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis. J Gastroenterol Hepatol. 11:1996;443-450.
31. Iredale JP, Murphy G, Hembry RM, Friedman SL, Arthur MJP. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1: implications for regulation of matrix degradation in liver. J Clin Invest. 90:1992;282-287.
32. Kordula T, Güttgemann I, Rose-John S, Roeb E, Osthues A, Tschesche H, Koi A, et al. Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human hepatoma cells (HepG2). FEBS. 131:1992;143-147.
33. Roeb E, Graeve L, Hoffmann R, Decker K, Edwards DR, Heinrich PC. Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures. Hepatology. 18:1993;1437-1442.
34. Nakatsukasa H, Ashida K, Higashi T, Ohguchi S, Tsuboi S, Hino N, Nouso K, Urabe Y, Kinugasa N, Yoshida K, Uematsu S, Ishizaki M, Kobayashi Y, Tsuji T. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas. Hepatology. 24:1996;82-88.